Cardiovascular disease and gene therapy research by Tenaya Therapeutics
Tenaya Therapeutics sees advances in symptom relief and cardiac hypertrophy measures
Tenaya Therapeutics has released new interim results from its ongoing clinical trial of TN-201, pointing to promising improvements in patient symptoms, functional capacity, and measures of cardiac ...
Tenaya Therapeutics CEO to present at Jefferies Global Healthcare Conference on June 4
Tenaya Therapeutics announced that its CEO, Faraz Ali, will deliver a presentation at the Jefferies Global Healthcare Conference. The event will take place on Thursday, June 4, 2026, at 3:10 p.m. ...
Tenaya Therapeutics presents new RIDGE-1 trial results showing arrhythmia reduction in PKP2-associated ARVC
Tenaya Therapeutics unveiled interim results from its RIDGE-1 Phase 1b/2 trial at #ASGCT, indicating consistent reductions in arrhythmias among adults with PKP2-associated arrhythmogenic right ...
Tenaya Therapeutics partners on parent attitudes survey for gene therapy in pediatric cardiomyopathy
Tenaya Therapeutics has joined forces with prominent pediatric advocacy group CCFheartkids and treatment center DdccLinic to conduct a survey among parents of children with cardiomyopathy ...
Eugene Braunwald legacy in HCM research honored by Tenaya Therapeutics
Tenaya Therapeutics joined the scientific community in paying tribute to Eugene Braunwald, MD, often called the father of modern cardiology, for his pioneering work in hypertrophic cardiomyopathy ...
Tenaya Therapeutics to present new clinical data from RIDGE-1 Phase 1b/2 TN-401 trial at ASGCT
Tenaya Therapeutics announced plans to deliver a late breaking oral presentation at the American Society of Gene and Cell Therapy (ASGCT) conference. The presentation will feature new clinical ...
Q4 and 2025 results drive business momentum, Tenaya Therapeutics outlines
Tenaya Therapeutics published its financial results for the fourth quarter and full year 2025, sharing updates on its business operations and development programs. The company highlighted ongoing ...
Tenaya Therapeutics announces positive data from Phase 1b/2 trial
Tenaya Therapeutics has revealed promising interim results from Cohort 1 of its RIDGE™-1 Phase 1b/2 clinical trial for TN-401, a gene therapy targeting PKP2-Associated Arrhythmogenic Right ...
Tenaya Therapeutics reveals MyPEAK-1 trial data
Tenaya Therapeutics announced the latest interim clinical data from its MyPEAK-1 Phase 1b/2 trial for TN-201. The data was shared by Dr. Milind Desai during the #AHA25 conference, highlighting ...
Tenaya Therapeutics unveils advancements at AHA25 sessions
Tenaya Therapeutics is gearing up to unveil significant advancements in their clinical and preclinical research efforts at the upcoming AHA25 Scientific Sessions. The sessions will feature ...
